| answer text |
<p>From 30 March 2019, the United Kingdom will no longer be a Member of the European
Union. However, under the terms of the implementation period agreement regulatory
standards and market access for all medicines will continue on current terms.</p><p>
</p><p>Both sides agree that for the implementation period to function effectively,
the UK will need to remain in step with the EU. In this context, the Withdrawal Agreement
will be underpinned by a duty of good faith, with a Joint Committee in place enabling
either side to raise issues or concerns. These arrangements will help ensure that
the implementation period works properly for both sides.</p><p> </p><p>Common rules
will remain in place and the UK may continue to participate in EU agencies and bodies
where the presence of the United Kingdom is necessary and is in the interests of the
EU, or where the discussion concerns acts addressed to the UK and its citizens. The
exact nature of this participation will be a matter for further discussion.</p><p>
</p><p>Regarding the future relationship, the Prime Minister's Mansion House speech
outlined that we will also explore the terms on which the UK could remain part of
the European Medicines Agency. While it would not be appropriate to pre-judge the
outcome of the negotiations, we will discuss with the EU and Member States how best
to continue cooperation in medicines regulation.</p>
|
|
